CDC Advisors Back Therapeutic to Prevent RSV in Infants
(MedPage Today) -- The CDC's Advisory Committee on Immunization Practices (ACIP) voted unanimously -- 10 to 0 -- in favor of nirsevimab (Beyfortus) for protecting a wide swath of at-risk infants from respiratory syncytial virus (RSV).
At a...
Source: MedPage Today Pediatrics - Category: Pediatrics Source Type: news
More News: Pediatrics | Respiratory Medicine